

Hematopoietic cell transplantation for Langerhans histiocytosis

Gabriele Zamperlini Netto^{1,2*} , Ana Paula Kuczynski Pedro Bom³ 

1. Hospital Israelita Albert Einstein – São Paulo (SP), Brazil.
2. Instituto de Tratamento do Câncer Infantil – São Paulo (SP), Brazil.
3. Hospital Pequeno Príncipe – Curitiba (PR), Brazil.

*Corresponding author: gabrielezn@hotmail.com

Section editor: Fernando Barroso Duarte 

Received: Sept. 15, 2025 • Accepted: Jan. 5, 2026

ABSTRACT

Langerhans cell histiocytosis is a rare myeloid neoplasm that primarily affects children. Initial treatment depends on risk stratification, but overall survival is excellent. Patient with high-risk disease with risk organ involvement can experience disease reactivation or refractoriness to front-line therapy. A standard approach is not established in the literature, with different reported strategies, including conventional chemotherapy, MAPK-inhibitors and allogeneic hematopoietic (HCT). Allogeneic HCT is supported by retrospective studies with overall survival ranging from 56 to 77% in the largest series. Disease status at the time of HCT and the conditioning regimen (reduced-intensity conditioning *versus* myeloablative conditioning) correlates with survival and toxicity. Most recently, reduced-intensity conditioning modality has emerged as the preferred option for patients diagnosed with Langerhans cell histiocytosis who require allogeneic HCT.

Keywords: Treatment Failure. Hematopoietic Stem Cell Transplantation. Histiocytosis. Langerhans-Cel. Transplantation Conditioning.

INTRODUCTION

Langerhans cell histiocytosis (LCH) is a rare disease, with an incidence of about five children per 1,000,000 under 15 years old¹. The clinical presentation is widely heterogeneous, varying from isolated lesions, with no or few symptoms to multisystem involvement and eventually organ dysfunction. The recent description of CD207+ in LCH lesions and the high prevalence of BRAF mutations, leading to activation of the MAPK signaling pathway as a oncogenic driver, support the classification of LCH as a myeloid neoplasia^{2,3}. Treatment of LCH is mostly based on a risk-adjusted approach: single lesions may respond to minimal or no treatment, whereas multisystem disease (MS-LCH) requires systemic therapy, mostly vinblastine and corticosteroids first-line therapy³. The last trial published by the Histiocyte Society showed excellent survival for both low- and high-risk patients, but reactivation occurred in almost 30% of patients⁴.

Patients with refractory disease have lower overall survival and risk of long-term health problems, including neurodegeneration, but no standard salvage therapy is established^{2,4,5}. Since MAPK mutations are commonly found in LCH patients, target therapies with BRAF or MEK/ERK inhibitors are recent alternatives explored for the treatment of recurrent/refractory diseases. Although results are encouraging with high-response rates^{6,7}, the standard approach has not been established with uncertainties regarding the clonal eradication and treatment duration^{8,9}. For those patients with refractory disease or gene-negative LCH, the HCT can be considered as an alternative therapy¹⁰.

The role of allogeneic hematopoietic cell transplantation (HCT) remains a subject of ongoing clinical discussion, as there are currently no randomized clinical trials evaluating its efficacy. Evidence guiding the treatment of high-risk or refractory cases is derived primarily from retrospective analyses.

Steiner et al.¹¹ explored the management of nine patients with refractory high-risk LCH with allogeneic HCT following a reduced-intensity conditioning (RIC) regimen. Treatment was well tolerated, and transplant-related mortality was lower than for historical myeloablative conditioning (MAC) regimens, with an overall survival of 78%.

In 2015, Veys et al.¹² published results from 87 high-risk patients transplanted from 1990 to 2013. A MAC regimen, typically utilizing total body irradiation or busulfan, were the standard until the early 2000s, after which RIC—largely consisting of fludarabine and melphalan—became the preferred approach. Although the three-year transplant-related mortality rates were comparable between the two groups—21% RIC *versus* 15% MAC—, the risk of recurrence was notably higher in patients receiving RIC regimens (28 *versus* 8%). Despite this disparity in relapse rates, the three-year overall survival remained statistically similar—77% RIC *versus* 71% MAC).

These findings were further supported by Kudo et al.¹³ in a retrospective study of 30 patients with refractory LCH, with no significant difference in the five-year overall survival between RIC (56.8%) and MAC (63.6%) modalities.

Disease status at the time of HCT has emerged as the primary prognostic factor; patients who achieve remission or partial remission prior to the procedure demonstrate a five-year overall survival of 100%, whereas those with active disease at the time of transplantation had a significantly lower survival rate of 54.5%. Conversely, factors such as the type of donor—frequently unrelated—and the source of stem cells, including bone marrow and umbilical cord blood, do not appear to exert a significant impact on overall survival rates^{9–14}.

There is no evidence for autologous HCT in LCH, mostly case reports based (Table 1 and 2).

Table 1. Hematopoietic cell transplant type.

	Autologous	Allogeneic
Localized (or RO -)	Not indicated	Not indicated
Multisystem and risk organ involvement (MS RO +)		
Recurrent/refractory	Not indicated	Indicated

RO: risk organ; MS: multisystem. Source: Elaborated by the authors.

Table 2. Hematopoietic cell transplant indications, graft, and stem cell source.

	Indication	Allogeneic
Multisystem and risk organ involvement (MS RO+)	Recurrent/refractory to first line or salvage therapy	MSD > MUD > MMD Bone marrow

RO: risk organ; MS: multisystem; MSD: matched sibling donor; MUD: matched unrelated donor; MMD: mismatched donor. Source: Nr and Kinderkrebsforschung¹⁵.

The role of HCT for the treatment of relapsed/refractory pediatric LCH under investigation in the most recent clinical trial (LCH-IV) conducted by the Histiocyte Society¹⁵, with no results published so far. A RIC HCT with alemtuzumab, fludarabine, and melphalan is an alternative considered for MS-LCH patients with risk organ involvement and refractory to first-line or to salvage therapy. Although RIC procedures have been preferred in recent years, there is no clear survival advantage of RIC *versus* MAC HCT. Considering LCH as myeloid neoplasia, myeloablative conditioning regimens with reduced toxicity protocols, including the addition of thiotepa or treosulfan to fludarabine and melphalan, are reasonable alternatives¹⁰ (Table 3 and 4).

Table 3. Conditioning.

HCT	Conditioning
RIC	Day -8 to -4: Alemtuzumab 0.2 mg/kg Day -7 to -3: Fludarabine 30 mg/m ² Day -2: Melphalan 140 mg/m ² Day -1: Rest Day 0: Stem cell infusion Day +8: GCSF 5 mcg/kg/day

HCT: hematopoietic cell transplant; RIC: reduced-intensity conditioning; GCSF: granulocyte-colony stimulating factor. Source: Nr and Kinderkrebsforschung¹⁵.

Table 4. Graft-versus-host-disease prophylaxis.

Hematopoietic cell transplant	Graft-versus-host-disease prophylaxis
	Day -3: Cyclosporine Day -3: Mycophenolate mofetil, if mismatched donor

Source: Nr and Kinderkrebsforschung¹⁵.

CONFLICT OF INTEREST

Nothing to declare.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable.

AUTHORS' CONTRIBUTIONS

Substantive scientific and intellectual contributions to the study: Netto GZ and Bom APKP. **Conception and design:** Netto GZ and Bom APKP. **Analysis and interpretation of data:** Netto GZ and Bom APKP. **Technical procedures:** Netto GZ and Bom APKP. **Statistics analysis:** Netto GZ and Bom APKP. **Manuscript writing:** Netto GZ and Bom APKP. **Final approval:** Netto GZ.

FUNDING

Not applicable.

DECLARATION OF USE OF ARTIFICIAL INTELLIGENCE TOOLS

The authors declare that no artificial intelligence tools were used in the preparation, writing, data analysis, or review of this manuscript.

ACKNOWLEDGEMENTS

Not applicable.

REFERENCES

- Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. *Pediatr Blood Cancer*. 2008;51(1):71–5. <https://doi.org/10.1002/pbc.21498>
- Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. *New Eng J Med*. 2018;379(9):856–68. <https://doi.org/10.1056/nejmra1607548>
- Héritier S, Emile JF, Hélias-Rodzewicz Z, Donadieu J. Progress towards molecular-based management of childhood Langerhans cell histiocytosis. *Arch Pediatr*. 2019;26(5):301–7. <https://doi.org/10.1016/j.arcped.2019.05.015>
- Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Aricò M, Astigarraga I, Braier J, Donadieu J, Henter JI, Janka-Schaub G, McClain KL, Weitzman S, Windebank K, Ladisch S; Histiocyte Society. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. *Blood*. 2013;121(25):5006–14. <https://doi.org/10.1182/blood-2012-09-455774>
- Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, Arico M, Piguet C, Gandemer V, Armari Alla C, Clausen N, Jeziorski E, Lambilliotte A, Weitzman S, Henter JI, Van Den Bos C; Salvage Group of the Histiocyte Society. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study. *Blood*. 2015;126(12):1415–23. <https://doi.org/10.1182/blood-2015-03-635151>

6. Héritier S, Emile JF, Barkaoui MA, Thomas C, Fraitag S, Boudjemaa S, Renaud F, Moreau A, Peuchmaur M, Chassagne-Clément C, Dijoud F, Rigau V, Moshous D, Lambilliotte A, Mazingue F, Kebaili K, Miron J, Jeziorski E, Plat G, Aladjidi N, Ferster A, Pacquement H, Galambrun C, Brugières L, Leverger G, Mansuy L, Paillard C, Deville A, Armari-Alla C, Lutun A, Gillibert-Yvert M, Stephan JL, Cohen-Aubart F, Haroche J, Pellier I, Millot F, Lescoeur B, Gandemer V, Bodemer C, Lacave R, Hélias-Rodzewicz Z, Taly V, Geissmann F, Donadieu J. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. *J Clin Oncol*. 2016;34(25):3023–30. <https://doi.org/10.1200/jco.2015.65.9508>
7. Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, Russo M, Hargrave D. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. *Blood Adv*. 2023;7(15):3806–15. <https://doi.org/10.1182/bloodadvances.2022008414>
8. Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, Kabbara N, Barkaoui M, Miron J, Chalard F, Milne P, Haroche J, Cohen F, Hélias-Rodzewicz Z, Simon N, Jehanne M, Kolenova A, Pagnier A, Aladjidi N, Schneider P, Plat G, Lutun A, Sonntagbauer A, Lehrnbecher T, Ferster A, Efremova V, Ahlmann M, Blanc L, Nicholson J, Lambilliotte A, Boudiaf H, Lissat A, Svojgr K, Bernard F, Elitzur S, Golan M, Evseev D, Maschan M, Idbaih A, Slater O, Minkov M, Taly V, Collin M, Alvarez JC, Emile JF, Héritier S. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. *J Clin Oncol*. 2019;37(31):2857–65. <https://doi.org/10.1200/jco.19.00456>
9. Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, Baidildina D, Popov A, Zhogov V, Semchenkova A, Litvin E, Kotskaya N, Cherniak E, Voronin K, Burtsev E, Bronin G, Vlasova I, Purbueva B, Fink O, Pristanskova E, Dzhukaeva I, Erega E, Novichkova G, Maschan A, Maschan M. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH. *Blood Adv*. 2023;7(18):5246–57. <https://doi.org/10.1182/bloodadvances.2022009067>
10. Meng G, Feng S, Wang Y. Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children. *Front Immunol*. 2025;16:1345855. <https://doi.org/10.3389/fimmu.2025.1345855>
11. Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E, Holter W, Vormoor J, Wawer A, Ouachee M, Woessmann W, Gadner H. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. *Bone Marrow Transplant*. 2005;36(3):215–25. <https://doi.org/10.1038/sj.bmt.1705015>
12. Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jürgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel G, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning. *Br J Haematol*. 2015;169(5):711–8. <https://doi.org/10.1111/bjh.13347>
13. Kudo K, Maeda M, Suzuki N, Kanegane H, Ohga S, Ishii E, Shioda Y, Imamura T, Imashuku S, Tsunematsu Y, Endo M, Shimada A, Koga Y, Hashii Y, Noguchi M, Inoue M, Tabuchi K, Morimoto A; Histiocytosis study group of the Japanese Society of Pediatric Hematology/Oncology. Nationwide retrospective review of hematopoietic stem cell transplantation in children with refractory Langerhans cell histiocytosis. *Int J Hematol*. 2020;111(1):137–48. <https://doi.org/10.1007/s12185-019-02760-5>
14. Akkari V, Donadieu J, Piguet C, Bordigoni P, Michel G, Blanche S, Casanova JL, Thomas C, Vilmer E, Fischer A, Bertrand Y; French Langerhans Cell Study Group. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: Experience of the French Langerhans Cell Study Group. *Bone Marrow Transplant*. 2003;31(12):1097–103. <https://doi.org/10.1038/sj.bmt.1704065>
15. Nr E, Kinderkrebsforschung SA. LCH-IV International Collaborative Treatment protocol for children and adolescents with Langerhans cell histiocytosis international sponsor. Available from: <http://www.histiocytosesociety.org>